PersonGen BioTherapeutics (Suzhou) Co., Ltd.
This is a clinical study of CD19 / CD20 CAR-T cell infusion in the treatment of relapsed or refractory hematological malignancies in CD19 / CD20 positive B cell lines. The aim of this study was to evaluate the efficacy and safety of autologous chimeric antigen receptor T cell infusion targeting CD19/CD20 in the treatment of relapsed or refractory CD19 / CD20 positive B cell line hematological malignancies.
CD19/CD20 CAR-T cell infusion
Early Phase 1
CD19 and CD20 are two proteins expressed in normal B cells and various B cell-derived hematological malignancies, including non Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (all) and chronic lymphoblastic leukemia (CLL). CD19 and CD20 are restricted to the surface of B cells. They are not expressed in hematopoietic stem cells, nor in other tissue cells. They exist in all stages of B cell development and differentiation. They are not lost from the cell surface until B cells differentiate into plasma cells. Clinical studies have found that CD19 and CD20 are excellent targets for immunotherapy of B-cell malignancies.The purpose of this study was to observe the efficacy and safety of treatment for patients with relapsed or refractory CD19 / CD20 positive B cell line hematological malignancies.
|Study Type :||Interventional|
|Estimated Enrollment :||30 participants|
|Masking:||None (Open Label)|
|Official Title:||CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies|
|Actual Study Start Date :||April 19, 2019|
|Estimated Primary Completion Date :||May 1, 2021|
|Estimated Study Completion Date :||June 1, 2021|
Experimental: CD19/CD20 CAR-T cell infusion
CD19/CD20 CAR-T cell infusion on relapsed or refractory hematological malignancies of CD19 / CD20+ B cell line
Drug: CD19/CD20 CAR-T cell infusion
|Ages Eligible for Study:||3 Years to 70 Years|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Anhui Provincial Hospital
Hefei, Anhui, China, 230000